8-KExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Exhibit Filing (May 2, 2024)

Filed May 2, 2024For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on May 2, 2024, to announce its financial results for the quarter ended March 31, 2024. While the 8-K itself primarily references a furnished press release for the detailed financial information, this filing indicates the company is providing its Q1 2024 operational and financial update to the market. Investors should refer to the press release (Exhibit 99.1) for the specific financial and operational details of the first quarter. This filing serves as the official notification mechanism for the release of this information, highlighting the company's ongoing financial performance and operational status. The information is furnished, not filed, meaning it is provided for disclosure purposes but does not carry the same legal implications under Section 18 of the Exchange Act.

Key Highlights

  • 1Alnylam Pharmaceuticals announced its Q1 2024 financial results via an 8-K filing on May 2, 2024.
  • 2The detailed financial and operational information is contained within a press release furnished as Exhibit 99.1.
  • 3This filing formally notifies the market of the company's Q1 2024 performance update.
  • 4Information furnished under Item 2.02 is for disclosure and not subject to Section 18 of the Exchange Act liabilities.
  • 5Investors need to consult the press release (Exhibit 99.1) for specific revenue, profit, and operational metrics.

Frequently Asked Questions

The specific financial results for the quarter ended March 31, 2024, are detailed in the press release furnished as Exhibit 99.1 to this 8-K filing.

This 8-K filing officially announces that Alnylam Pharmaceuticals has released its Q1 2024 financial results and provides a reference to the press release containing those details.

No, the information provided under Item 2.02 and in Exhibit 99.1 is furnished, not filed. This means it is for public disclosure but does not carry the same legal liabilities under Section 18 of the Securities Exchange Act of 1934 as a formally filed document.

Investors should focus on obtaining and reviewing the press release (Exhibit 99.1) to understand Alnylam's Q1 2024 revenue, profitability, operational progress, and any forward-looking statements or guidance provided by the company.